PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
ORKA Oruka Therapeutics
- 11.180
- -0.250-2.19%
Close Feb 14 16:00 ET
- 11.180
- 0.0000.00%
Post 20:01 ET
391.28MMarket Cap-29.42P/E (TTM)
11.905High10.830Low248.88KVolume11.170Open11.430Pre Close2.80MTurnover1.06%Turnover RatioLossP/E (Static)35.00MShares33.00052wk High1.15P/B261.68MFloat Cap10.19752wk Low--Dividend TTM23.41MShs Float40838092.445Historical High--Div YieldTTM9.41%Amplitude10.068Historical Low11.246Avg Price1Lot Size
About Oruka Therapeutics Company
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Company Profile
SymbolORKA
Company NameOruka Therapeutics
Listing DateAug 8, 1997
CEODr. Lawrence Otto Klein, PhD
MarketNASDAQ
Fiscal Year Ends12-31
Address855 Oak Grove Avenue,Suite 100
CityMenlo Park
ProvinceCalifornia
CountryUnited States of America
Zip Code94025
Phone1-650-606-7910
Websitehttp://www.orukatx.com
Company Executives
- Name
- Position
- Salary
- Dr. Lawrence Otto Klein, PhD
- Director, President and Chief Executive Officer
- --
- Dr. Joana Goncalves, M.D.
- Chief Medical Officer
- --
- Arjun Agarwal
- Senior Vice President, Finance and Treasurer
- --
- Dr. Samarth Kulkarni, PhD
- Chairman of the Board
- --
- Dr. Carl Dambkowski, M.D.
- Independent Director
- --
- Kristine M. Ball
- Independent Director
- --
- Peter Harwin
- Independent Director
- --
- Dr. Cameron Turtle, D.Phil.
- Independent Director
- --
- Paul T. Quinlan PhD
- General Counsel and Secretary
- --
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025